Essential medicines and health products

Substandard and Falsified (SF) Medical Products

The existence of substandard and falsified (SF) medical products is an unacceptable risk to public health. They affect every region of the world, and medicines from all major therapeutic categories have been reported, including vaccines and diagnostics. They harm patients and undermine confidence in medical products, healthcare professionals and health systems. WHO is working with stakeholders to minimize the risks from SF medical products by collecting data and transferring knowledge and good practices to countries.


News and Announcements

On 29 May 2017 at the Seventieth World Health Assembly, a decision was agreed to have “Substandard and Falsified (SF) medical products” as the term to be used in the name of the Member State mechanism and in all future documentation on the subject of medical products of this type.

WHO has highlighted this definition and terminology change in a news release for the Seventieth World Health Assembly, available at the following link:

The SF Medical Products Group kindly asks for your patience as we work to update this website, as appropriate.
Please contact us at rapidalert@who.int should you have any questions.

Recent and Forthcoming Events

  • 26-29 June 2017 – Tennessee, United States of America

    UTHSC’s APEC Center of Excellence Pilot Program for Global Medical Product Quality and Supply Chain Security: Protecting Patient Safety in the Global Marketplace Through GDPs and Product Security Measures

  • 28-30 June 2017 –Ouagadougou, Burkina Faso

    Joint World Health Organization/West African Health Organization meeting on improving access to certified quality medicines in the Economic Community of West Africa States area

  • 10-14 July 2017 – Massachusetts, United States of America

    Quality of Medical Products and Public Health Course at Boston University School of Public Health

Contact us

SF Medical Products Group
Essential Medicines and Health Products
World Health Organization
20 avenue Appia
1211 Geneva 27
Switzerland
E-mail: rapidalert@who.int